321 Harrison Avenue
Suite 900
Boston, MA 02118
United States
(617) 949-2643
https://www.monterosatx.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 133
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Markus Warmuth M.D. | President, CEO & Director | 901,35k | N/D | 1972 |
Dr. Owen B. Wallace Ph.D. | Chief Scientific Officer | 630,68k | N/D | 1969 |
Dr. Filip Janku M.D., Ph.D. | Chief Medical Officer | 658,66k | N/D | 1975 |
Ms. Jennifer Champoux | Chief People & Operations Officer | N/D | N/D | N/D |
Dr. Sharon Townson Ph.D. | Chief Technology Officer | N/D | N/D | 1975 |
Dr. John C. Castle Ph.D. | Chief Data & Information Officer | N/D | N/D | 1972 |
Mr. Andrew Funderburk | Senior VP and Head of IR & Strategic Finance | N/D | N/D | N/D |
Mr. Philip Nickson J.D., Ph.D. | General Counsel | N/D | N/D | 1979 |
Mr. Magnus Walter DPHIL | Senior Vice President of Drug Discovery | N/D | N/D | N/D |
Mr. Edmund Dunn | Vice President & Corporate Controller | N/D | N/D | 1966 |
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
L'ISS Governance QualityScore di Monte Rosa Therapeutics, Inc. al 1 aprile 2024 è 9. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 9; diritti degli azionisti: 8; retribuzione: 8.